Skip to main content
Back to OrbiMed

OrbiMed's Oncology Portfolio

Browse 10 Oncology companies funded by OrbiMed. See funding amounts, founder contacts, and investment details.

Oncology Companies
10
Total Funding in Oncology
$854.9M

Oncology Portfolio Companies (10)

Export
BiopharmaBiotechnologyLife ScienceOncology

Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.

Pacific Palisades, United States
May 2026
Post-IPO Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareMedicalOncologyTherapeutics

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

San Diego, United States
September 2025
$60.0M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareHealth DiagnosticsMedicalOncology

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Philadelphia, United States
May 2025
$38.0M
Series D

Founder Contacts

19,000+ verified contacts

BiotechnologyOncologyTherapeutics

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

Seattle, United States
February 2024
$112.0M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareOncologyPharmaceuticalProduct Research

OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.

New York, United States
January 2024
$100.0M
Series A

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyHealth CareOncologyPharmaceuticalTherapeutics

BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.

San Diego, United States
December 2025
$84.0M
Series B

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyHealth CareOncology

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.

Beltsville, United States
November 2025
$21.5M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyClinical TrialsHealth CareOncologyPharmaceuticalTherapeutics

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

Cambridge, United States
October 2025
$155.3M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareOncologyPharmaceutical

Apollomics is a biopharmaceutical company discovering and developing mono- and combination- oncology therapies to harness the immune system.

Foster City, United States
September 2025
$4.1M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyMedical DeviceOncology

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Cambridge, United States
April 2024
$280.0M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

Explore OrbiMed's Full Portfolio

View all companies funded by OrbiMed across every industry and funding stage.

View Full OrbiMed Portfolio